Peptide Comparison
Retatrutide vs Mazdutide
Editorial breakdown of mechanism, evidence, decision criteria, and the misconceptions worth calling out.
This combination is flagged
Two glucagon-receptor agonists in the same regimen: High risk per peptide research literature. Overlapping glucagon-receptor activation drives hepatic glucose output, hepatic lipid mobilization, and resting heart rate; stacking compounds metabolic and cardiovascular load with no clinical precedent.
Data-derived verdict
Retatrutide and Mazdutide share the glp-1 / glucagon-agonist classes and carry roughly equivalent evidence (Phase 3 / Phase 3 (China)). On the catalogued data layer Retatrutide has a slight edge: more cited sources or efficacy data on file. For most research framings either pick is defensible; Retatrutide's evidence base is currently denser.
Evidence at a glance
FDA-approved Phase 3 Phase 2 / approved abroad Anecdotal + animal Preclinical / flagged
Side-by-side
| Retatrutide | Mazdutide | |
|---|---|---|
| Class | GIP/GLP-1/glucagon triple agonist | GLP-1/glucagon dual agonist |
| Drug class | Metabolic & Weight | Metabolic & Weight |
| Mechanism | Simultaneous activation of GIP, GLP-1, and glucagon receptors for incretin + energy expenditure effects | Oxyntomodulin analog; activates GLP-1 and glucagon receptors |
| Route | SC injection | SC injection |
| Half-life | ~6 days | Long-acting weekly |
| Dosage (research) | 2 mg SC weekly (TRIUMPH Phase 3 starting dose, escalate by 2 mg every fourth week per protocol, trial doses 1, 2, 4, 8, and 12 mg/wk) | 3-9 mg SC weekly |
| Evidence tier | Phase 3 | Phase 3 (China) |
| Research depth | 217 indexed | 126 indexed |
| Availability | Investigational | Investigational |
| Reported risks | GI side effects; Phase 3 ongoing; long-term safety unknown | GI effects; no Western approval |
Reported research data only. "Studied for" and "reported in literature" describe published research focus, not clinical recommendation. Most peptides catalogued here are not FDA-approved for human use.
Frequently asked questions
Should I pick Retatrutide or Mazdutide?
Retatrutide and Mazdutide share the glp-1 / glucagon-agonist classes and carry roughly equivalent evidence (Phase 3 / Phase 3 (China)). On the catalogued data layer Retatrutide has a slight edge: more cited sources or efficacy data on file. For most research framings either pick is defensible; Retatrutide's evidence base is currently denser.
What is the difference between Retatrutide and Mazdutide?
Retatrutide is classed as GIP/GLP-1/glucagon triple agonist; Mazdutide is classed as GLP-1/glucagon dual agonist. Reported mechanism: Retatrutide, Simultaneous activation of GIP, GLP-1, and glucagon receptors for incretin + energy expenditure effects; Mazdutide, Oxyntomodulin analog; activates GLP-1 and glucagon receptors. Reported half-life: Retatrutide, ~6 days; Mazdutide, Long-acting weekly. Routes in published studies: Retatrutide, SC injection; Mazdutide, SC injection.
Which has stronger evidence, Retatrutide or Mazdutide?
Retatrutide and Mazdutide sit on the same rung of PeptideHelper.org's five-step evidence scale, which runs from preclinical to FDA-approved. Retatrutide is graded Phase 3, with 29 cited sources on its reference page and 217 indexed studies. Mazdutide is graded Phase 3 (China), with 23 cited sources on its reference page and 126 indexed studies.
Which is more accessible, Retatrutide or Mazdutide?
Neither Retatrutide nor Mazdutide is an FDA-approved drug. Catalog status: Retatrutide, Investigational; Mazdutide, Investigational.
Are Retatrutide and Mazdutide ever combined?
Retatrutide and Mazdutide appear together in no stack catalogued on PeptideHelper.org. PeptideHelper.org's interaction engine flags the pair: Two glucagon-receptor agonists in the same regimen, high risk.
Open the PeptideHelper.org compare tool to add more compounds to this side-by-side and filter by evidence tier interactively.
Loading interactive view…